The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

This page serves as your comprehensive resource hub, featuring the latest medications, both generic and brand-name, along with essential treatment options for Managing SGLT2 Inhibitors ...

Farxiga (dapagliflozin) is an orally administered, brand-name medication classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor. SGLT2 inhibitors help lower blood sugar by causing the ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors were more cardioprotective in older people, but reduced HbA1c less with age. GLP-1 receptor agonists ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Comparative ...

Older adults had a lower risk for major adverse CV events than younger adults with SGLT2 inhibitors. Perspective from Sara Cromer, MD SGLT2 inhibitors confer greater risk reductions for major ...

sodium-glucose transporter 2 (SGLT2) inhibitors — these reduce the amount of glucose reabsorbed by the kidneys, meaning that it is excreted in the urine. A meta-analysis, published in the ...